| --- | --- | --- | --- | --- | |----------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | Commitment to a Cure | | | | | | | | | | | | Corporate Presentation March 2022 | | | | | | NASDAQ: CLLS EURONEXT GROWTH: ALCLS.PA | | | | | | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Cellectis S.A. (NASDAQ:CLLS) Q4 2021 Results Earnings Conference Call March 4, 2022 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Carrie Brownstein - Chief Medical Officer Bing Wang - Chief Financial Officer David Sourdive - Executive Vice President, CMC and Manufacturing Steve Doares - Chief Regulatory and Compliance Officer Conference Call Participants Yigal Nochomovitz - Citigroup Gena Wang - Barclays Capital David Windley - Jefferies Raju ...

EXHIBIT 99.1 Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results Encouraging preliminary results from BALLI-01 study (evaluating UCART22) in relapsed/refractory B-cell Acute Lymphoblastic Leukemia presented at ASH 2021 annual meeting; BALLI-01 currently enrolling at DL3 On track for planned 2022 IND submission for UCART20x22, our first allogeneic dual CAR T-cell product candidate, in B-cell non-Hodgkin's Lymphoma Two manufacturing sites are now fully operational; ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Cellectis S.A. (NASDAQ:CLLS) Q3 2021 Results Conference Call November 5, 2021 8:00 AM ET Company Participants Andre Choulika - Chief Executive Officer Eric Dutang - Chief Financial Officer Carrie Brownstein - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Gena Wang - Barclays Kelsey Goodwin - Guggenheim Kelly Shi - Jeffries Hartaj Singh - Oppenheimer & Co Jack Allen - Baird Raju Prasad - William Blair Nick Abbott - Wells Fargo Ingrid Gafanhão - Kempen & Co Operator Greeting ...

Cellectis S.A. (NASDAQ:CLLS) Q2 2021 Earnings Conference Call August 6, 2021 8:00 AM ET Company Participants Eric Dutang - Chief Financial Officer André Choulika - Chief Executive Officer Carrie Brownstein - Chief Medical Officer Steve Doares - Senior Vice President, US Manufacturing Conference Call Participants Gena Wang - Barclays Michael Schmidt - Guggenheim Kelly Shi - Jeffries Yigal Nochomovitz - Citi Jack Allen - Baird Hartaj Singh - Oppenheimer Sami Corwin - William Blair Operator Greetings. Welcome ...

Cellectis S.A. (NASDAQ:CLLS) Q4 2020 Earnings Conference Call March 5, 2021 8:00 AM ET Company Participants Simon Harnest - Senior Vice President, Corporate Strategy and Finance André Choulika - Chief Executive Officer Carrie Brownstein - Chief Medical Officer Eric Dutang - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC Gena Wang - Barclays Salveen Richter - Goldman Sachs Hartaj Singh - Oppenheimer & Company Yigal Nochomovitz - Citigroup Wangzhi Li - Ladenb ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Cellectis S.A. (NASDAQ:CLLS) Q3 2020 Earnings Conference Call November 6, 2020 8:00 AM ET Company Participants Simon Harnest – Senior Vice President, Corporate Strategy and Finance André Choulika – Chief Executive Officer Carrie Brownstein – Chief Medical Officer Eric Dutang – Chief Financial Officer Conference Call Participants Gena Wang – Barclays Yigal Nochomovitz – Citigroup Jim Birchenough – Wells Fargo Kelsey Goodwin – Guggenheim Salveen Richter – Goldman Sachs Hartaj Singh – Oppenheimer & Company Wan ...

cellectis EDITING LIFE COMMITMENT TO A CURE | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------ ...